Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Kiadis Pharma Receives Regulatory Approval from Health Canada

Published: Thursday, February 28, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
Company has received No Objection Letter for its new clinical study with ATIR™.

Kiadis Pharma B.V. has announced that it has received the No Objection Letter from Health Canada for its new clinical study with ATIR™.

This study will be a Phase II international multi-center study with clinical sites in Canada and Belgium.

Up to 23 patients will be treated in this study to corroborate and extend the safety and efficacy results from Kiadis Pharma‘s previous Phase I/II clinical study with ATIR™.

The coordinating investigator for the study will be Denis-Claude Roy, MD, professor of medicine at the University of Montreal. ATIR™ is a cell-based product designed to enable stem cell transplantations from mismatched (haploidentical) family donors.

“We are very happy that after having received approval from the Research Ethics Board of the Maisonneuve-Rosemont Hospital, we have now also gained approval from Health Canada and can commence with our new clinical study in Canada”, commented Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma.

Ruediger continued, “This study will be an important step forward in developing ATIR™ as an innovative therapeutic option for severely diseased blood cancer patients. Today, many of these patients die because a matched stem cell donor cannot be found.”

Dr. Denis-Claude Roy added: “We are excited that we can start this Phase II clinical study with ATIR™ in which we will treat blood cancer patients for whom a matched donor is not available for a standard transplantation procedure. This study provides these patients with the opportunity to receive a stem cell transplantation from a family member with ATIR™ added as an adjunctive treatment to provide rapid and potent immune protection and minimize post-transplant risks.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™
67% survival demonstrated after 5 years and no transplant related mortalities.
Tuesday, September 17, 2013
Scientific News
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos